DK1043025T3 - Behandling af nyrecellekarcinom - Google Patents

Behandling af nyrecellekarcinom

Info

Publication number
DK1043025T3
DK1043025T3 DK00107100T DK00107100T DK1043025T3 DK 1043025 T3 DK1043025 T3 DK 1043025T3 DK 00107100 T DK00107100 T DK 00107100T DK 00107100 T DK00107100 T DK 00107100T DK 1043025 T3 DK1043025 T3 DK 1043025T3
Authority
DK
Denmark
Prior art keywords
treatment
cell carcinoma
renal cell
renal
carcinoma
Prior art date
Application number
DK00107100T
Other languages
Danish (da)
English (en)
Inventor
Esther Helen Rose
Mary Ellen Rybak
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK1043025T3 publication Critical patent/DK1043025T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • A61K38/212IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
DK00107100T 1999-04-08 2000-04-06 Behandling af nyrecellekarcinom DK1043025T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28835999A 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
DK1043025T3 true DK1043025T3 (da) 2005-07-04

Family

ID=23106761

Family Applications (2)

Application Number Title Priority Date Filing Date
DK00107100T DK1043025T3 (da) 1999-04-08 2000-04-06 Behandling af nyrecellekarcinom
DK05002952T DK1535623T3 (da) 1999-04-08 2000-04-06 Nyrecelle-carcinom behandling

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK05002952T DK1535623T3 (da) 1999-04-08 2000-04-06 Nyrecelle-carcinom behandling

Country Status (24)

Country Link
EP (2) EP1535623B1 (pt)
JP (2) JP3712914B2 (pt)
CN (1) CN1367702A (pt)
AR (1) AR029160A1 (pt)
AT (2) ATE419002T1 (pt)
AU (2) AU777406B2 (pt)
BR (1) BR0009644A (pt)
CA (1) CA2303752A1 (pt)
CO (1) CO5170412A1 (pt)
CY (1) CY1108919T1 (pt)
DE (2) DE60041291D1 (pt)
DK (2) DK1043025T3 (pt)
ES (2) ES2239953T3 (pt)
HK (2) HK1032533A1 (pt)
HU (1) HU230271B1 (pt)
MX (1) MXPA00003401A (pt)
MY (1) MY155221A (pt)
NO (1) NO328983B1 (pt)
NZ (1) NZ514629A (pt)
PE (1) PE20010026A1 (pt)
PT (2) PT1043025E (pt)
TW (2) TW200526243A (pt)
WO (1) WO2000061174A2 (pt)
ZA (1) ZA200108169B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1043025T3 (da) * 1999-04-08 2005-07-04 Schering Corp Behandling af nyrecellekarcinom
CA2648077A1 (en) * 2006-03-31 2007-11-08 Schering Corporation Parenteral low dose type 1 interferons for bladder cancer
TW200901989A (en) * 2007-04-10 2009-01-16 Wyeth Corp Anti-tumor activity of CCI-779 in papillary renal cell cancer
US8053430B2 (en) 2008-10-06 2011-11-08 Haraldsson Boerje Treatment of renal cell carcinoma
JP2013523726A (ja) 2010-04-01 2013-06-17 オンコレナ エービー 腎細胞癌の改良された治療
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
WO2018215936A1 (en) 2017-05-24 2018-11-29 Novartis Ag Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5766582A (en) * 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
PT1066059E (pt) * 1998-03-26 2005-10-31 Schering Corp Formulacoes para proteccao de conjugados de peg-interferao alfa
DK1043025T3 (da) * 1999-04-08 2005-07-04 Schering Corp Behandling af nyrecellekarcinom

Also Published As

Publication number Publication date
DK1535623T3 (da) 2009-04-27
AU2004242454B2 (en) 2007-02-15
TWI310314B (en) 2009-06-01
EP1043025A2 (en) 2000-10-11
CO5170412A1 (es) 2002-06-27
HUP0200781A2 (en) 2002-08-28
JP2001288110A (ja) 2001-10-16
NO328983B1 (no) 2010-07-05
DE60041291D1 (de) 2009-02-12
AU777406B2 (en) 2004-10-14
PE20010026A1 (es) 2001-02-05
WO2000061174A3 (en) 2001-01-25
AU2004242454A1 (en) 2005-01-20
AU4204400A (en) 2000-11-14
BR0009644A (pt) 2002-01-08
JP2000319196A (ja) 2000-11-21
DE60020442D1 (de) 2005-07-07
HU230271B1 (hu) 2015-11-30
NO20014851L (no) 2001-12-07
DE60020442T2 (de) 2006-05-04
HUP0200781A3 (en) 2002-09-30
CA2303752A1 (en) 2000-10-08
CN1367702A (zh) 2002-09-04
MXPA00003401A (es) 2002-03-08
EP1043025B1 (en) 2005-06-01
HK1032533A1 (en) 2001-07-27
ZA200108169B (en) 2003-01-06
CY1108919T1 (el) 2014-07-02
JP3712914B2 (ja) 2005-11-02
AR029160A1 (es) 2003-06-18
HK1075417A1 (en) 2005-12-16
PT1043025E (pt) 2005-09-30
NZ514629A (en) 2004-02-27
EP1043025A3 (en) 2000-12-20
ES2319777T3 (es) 2009-05-12
JP4721488B2 (ja) 2011-07-13
EP1535623B1 (en) 2008-12-31
TW200526243A (en) 2005-08-16
MY155221A (en) 2015-09-30
ATE296638T1 (de) 2005-06-15
EP1535623A1 (en) 2005-06-01
NO20014851D0 (no) 2001-10-05
ES2239953T3 (es) 2005-10-16
WO2000061174A2 (en) 2000-10-19
PT1535623E (pt) 2009-03-19
ATE419002T1 (de) 2009-01-15

Similar Documents

Publication Publication Date Title
DE60003693D1 (de) Kanalstromfilter
DE60037170D1 (de) Leitschaufel
DE10084903T1 (de) Polyetherpolyurethan
DE60021217D1 (de) Ostomievorrichtung
ATE319461T1 (de) Simethicon enthaltendes abführmittel
DK1210085T3 (da) Farmaceutiske oplösninger af levosimendan
DK1176964T3 (da) Brug af ET743 til behandling af cancer
DE60024711D1 (de) Leitschaufel
DE60037233D1 (de) Hämofiltrationsvorrichtung
DE60024400D1 (de) Empfangsgerät
HK1075417A1 (en) Renal cell carcinoma treatment
FI991476A0 (fi) Alipäästösuodatin
DK1155050T3 (da) Fremstilling af polyolefin
DE60007475D1 (de) Filter
NO20013596D0 (no) Slambehandling
ATE302165T1 (de) Wasserbehandlung
DK1088010T3 (da) Fremstilling af polyolefiner
DE59911042D1 (de) Planarfilter
DE50002979D1 (de) Kabelkanal
DK199901559A (da) Stomi/brok-bandage
PT1020132E (pt) Aba de puxar destacavel
DE60039142D1 (de) Energiefilter
FI113576B (fi) Suodatin
DK1227795T3 (da) Lipidkompleks af alkycycliner
NO994200D0 (no) Vannfilter